Skip to content
Home
Visit our other Journals
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Diseases
Alzheimer's Disease
Dementia
Dementia with Lewy Bodies
Frontotemporal Dementia
Vascular Dementia
Mild Cognitive Impairment
View all Diseases
Topics
Diagnostics
Biology
Biomarkers
Treatment
Clinical Care
Prevention
View all Topics
Conferences
AAIC 2023
BNA 2023
AD/PD 2023
ARUK 2023
CTAD 2022
AAIC 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Mild Cognitive Impairment
5:21
Clinical robustness of CSF pTau/Aβ42 ratio for Alzheimer’s disease diagnosis
Henrik Schinke
• 15 Dec 2022
2:11
Promise of microRNAs as Alzheimer’s disease markers
Bruno Steinkraus
• 1 Dec 2022
10:42
Mild behavioral impairment is associated with abnormal AD CSF biomarker profiles in MCI
Zahinoor Ismail
• 15 Dec 2022
2:36
The regulatory role of nicotinic receptors in cognitive functioning
Paul Newhouse
• 23 Nov 2022
1:36
How effective are cholinergic agents beyond MCI?
Paul Newhouse
• 23 Nov 2022
3:11
Clinical implementations of AlzoSure Predict
Paul Kinnon
• 28 Nov 2022
9:01
Longitudinal clinical outcomes of tau-PET-positive individuals
Alexis Moscoso Rial
• 15 Dec 2022
5:34
Associations between predicted brain age and Alzheimer’s Disease biomarkers
Irene Cumplido-Mayoral
• 25 Nov 2022
3:37
The diagnostic and prognostic performance of U-p53AZ as a blood-based biomarker for AD
Paul Kinnon
• 21 Nov 2022
1:52
The future of SAGE-718 in Alzheimer’s disease treatment
Aaron Koenig
• 28 Nov 2022
6:13
Biomarkers for early detection of Alzheimer’s disease: microRNAs
Bruno Steinkraus
• 1 Dec 2022
1:42
Insights into the upcoming LIGHTWAVE trial using SAGE-718 to treat patients with MCI and early AD
Aaron Koenig
• 28 Nov 2022
1:00
New mechanisms to treat Alzheimer’s disease by targeting the NMDA pathway
Aaron Koenig
• 28 Nov 2022
4:37
Long-term transdermal nicotine for the treatment of mild cognitive impairment
Paul Newhouse
• 23 Nov 2022
2:05
Phase II clinical trial of SAGE-718 for the treatment of MCI and early AD
Aaron Koenig
• 28 Nov 2022
4:01
EXERT: why was strength/balance training as effective as cardio in preventing cognitive decline?
Laura Baker
• 26 Jul 2022
Previous
1
2
3
4
5
Next